Have a feature idea you'd love to see implemented?
Let us know!
CABA Cabaletta Bio Inc
Price (delayed)
$1.87
Market cap
$91.4M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.16
Enterprise value
-$63.98M
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative,
Highlights
The equity has contracted by 13% from the previous quarter but it has grown by 8% YoY
CABA's debt has surged by 106% since the previous quarter
CABA's net income has dropped by 67% year-on-year and by 16% since the previous quarter
Key stats
What are the main financial stats of CABA
Market
Valuations
Earnings
Shares outstanding
48.88M
Market cap
$91.4M
Enterprise value
-$63.98M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.52
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$104.16M
EBITDA
-$97.08M
Free cash flow
-$83.57M
Per share
Balance sheet
Liquidity
EPS
-$2.16
Free cash flow per share
-$1.71
Book value per share
$3.57
Revenue per share
$0
TBVPS
$4.18
Total assets
$204.41M
Total liabilities
$30.17M
Debt
$15.22M
Equity
$174.24M
Working capital
$162.63M
Debt to equity
0.09
Current ratio
8.11
Quick ratio
8
Net debt/EBITDA
1.6
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.5%
Return on equity
-50.1%
Return on invested capital
-261.6%
Return on capital employed
-57.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CABA stock price
How has the Cabaletta Bio stock price performed over time
Intraday
-17.26%
1 week
-50.53%
1 month
-58.63%
1 year
-89.39%
YTD
-91.76%
QTD
-60.38%
Financial performance
How have Cabaletta Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$114.5M
Net income
-$104.16M
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 69% YoY and by 14% from the previous quarter
CABA's net income has dropped by 67% year-on-year and by 16% since the previous quarter
Growth
What is Cabaletta Bio's growth rate over time
Valuation
What is Cabaletta Bio stock price valuation
P/E
N/A
P/B
0.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
CABA's EPS is down by 26% YoY and by 13% QoQ
CABA's price to book (P/B) is 81% lower than its last 4 quarters average of 2.7 and 75% lower than its 5-year quarterly average of 2.1
The equity has contracted by 13% from the previous quarter but it has grown by 8% YoY
Efficiency
How efficient is Cabaletta Bio business performance
The ROIC has contracted by 46% YoY and by 34% from the previous quarter
Cabaletta Bio's ROE has decreased by 14% from the previous quarter and by 7% YoY
Cabaletta Bio's return on assets has decreased by 12% QoQ and by 5% YoY
Dividends
What is CABA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CABA.
Financial health
How did Cabaletta Bio financials performed over time
Cabaletta Bio's total liabilities has soared by 144% YoY and by 69% from the previous quarter
Cabaletta Bio's quick ratio has decreased by 48% YoY and by 30% QoQ
CABA's debt is 91% smaller than its equity
Cabaletta Bio's debt to equity has soared by 200% YoY and by 125% from the previous quarter
CABA's debt has surged by 106% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.